Table 4.
Summary of outcomes in G-CSF versus control/placebo groups
| Outcomes of G-CSF versus control/placebo groups | |||||
|---|---|---|---|---|---|
|
| |||||
| Outcome | No of comparison groups | Effect | 95% CI | P | I2 |
| Neutrophil engraftment | |||||
| RCTs | 3* | -0.94 (SMD) | -1.38; -0.51 | 0.21 | 35% |
| NRSs | 7* | -1.20 (SMD) | -1.43; -0.96 | <0.01 | 74% |
| Platelet engraftment | |||||
| RCTs | 3* | -0.10 (SMD) | -0.44; -0.64 | 0.03 | 72% |
| NRSs | 4* | 0.03 (SMD) | -0.79; 0.86 | <0.01 | 86% |
| ac GVHD II-IV | |||||
| RCTs | 6 | 0.91 (RR) | 0.71; 1.17 | 0.85 | 0% |
| NRSs | 11* | 1.10 (RR) | 1.00; 1.22 | 0.06 | 43% |
| ch GVHD | |||||
| RCTs | 4 | 1.01 (RR) | 0.79; 1.28 | 0.88 | 0% |
| NRSs | 10* | 1.11 (RR) | 1.00; 1.22 | 0.02 | 53% |
| Hospital stay | |||||
| RCTs | 3* | -0.64 (SMD) | -1.30; 0.03 | 0.02 | 74% |
| NRSs | 4* | 0.28 (SMD) | -0.16; 0.73 | <0.01 | 92% |
| Overall survival | |||||
| RCTs | 4 | 1.06 (RR) | 0.90; 1.26 | 0.95 | 0% |
| NRSs | 6 | 0.98 (RR) | 0.86, 1.13 | 0.02 | 63% |
*
After excluding outliers (the values that are not marked with * did not have outliers in the analysis);
SMD: Standard mean difference; RCT: Randomized controlled trial; NRS: Non-randomized studies.